Document Detail


Feasibility of using plasma rather than serum in first and second trimester multiple marker Down's syndrome screening.
MedLine Citation:
PMID:  23277614     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare maternal plasma with serum for measuring markers currently used in first and second trimester screening for Down's syndrome.
SETTING: A laboratory-based investigation of two sample types in assays used in prenatal screening for Down's syndrome.
METHODS: A paired data-set included both plasma and serum from 101 pregnant women. A nested case/control data-set included only plasma samples from 34 first and 23 second trimester Down's syndrome pregnancies, each matched with six euploid controls. Analyte levels were measured and converted to multiples of the median (MoM).
RESULTS: In the paired data-set, each of the five analytes (alphafetoprotein, unconjugated estriol, human chorionic gonadotropin, inhibin-A and pregnancy-associated plasma protein A) in serum and plasma was highly correlated (r > 0.970) and after conversion to MoM, the resulting distributions were equivalent (P > 0.7). In the matched data-set, plasma-based median MoM levels in cases were consistent with the published serum counterparts for all markers.
CONCLUSIONS: This study provides strong evidence that current serum-based prenatal screening can be performed equally well using plasma samples. This may prove useful, especially if secondary screening using a DNA-based test requires maternal plasma.
Authors:
Geralyn M Lambert-Messerlian; Glenn E Palomaki; Elizabeth E Eklund; Edward M Kloza; Louis M Neveux; Maureen G Phipps; Jacob A Canick
Related Documents :
23357564 - An evaluation of 2,4-dichlorophenoxyacetic acid in the amphibian metamorphosis assay an...
25017764 - Prognostic biomarkers for acute graft-versus-host-disease risk following cyclophosphami...
24996614 - Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans.
23112844 - Neonatal thyroid-stimulating hormone concentrations in belgium: a useful indicator for ...
6602444 - Difficulties in the diagnosis of congenital adrenal hyperplasia in early infancy: the 1...
2923074 - Aspartame and its constituent amino acids: effects on prolactin, cortisol, growth hormo...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-12-31
Journal Detail:
Title:  Journal of medical screening     Volume:  19     ISSN:  1475-5793     ISO Abbreviation:  J Med Screen     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2013-03-14     Completed Date:  2013-09-05     Revised Date:  2013-11-05    
Medline Journal Info:
Nlm Unique ID:  9433359     Medline TA:  J Med Screen     Country:  England    
Other Details:
Languages:  eng     Pagination:  164-70     Citation Subset:  IM    
Affiliation:
Women and Infants Hospital, 70 Elm Street, 2nd Floor, Providence, RI 02903, USA. gmesserlian@wihri.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Markers / analysis,  blood*
Blood Chemical Analysis / methods
Case-Control Studies
Down Syndrome / blood,  diagnosis*
Feasibility Studies
Female
Gestational Age
Humans
Mass Screening / methods
Plasma / chemistry*
Pregnancy
Pregnancy Trimester, First / blood*
Pregnancy Trimester, Second / blood*
Prenatal Diagnosis*
Serum / chemistry*
Validation Studies as Topic
Chemical
Reg. No./Substance:
0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inference for the physical sciences.
Next Document:  Risk of Adult Schizophrenia and Its Relationship to Childhood IQ in the 1958 British Birth Cohort.